Multiple Myeloma

MULTIPLE MYELOMA ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

PTSD in Cancer Patients: What Providers Need to Know

Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes.
How to Prevent a Cyberattack from Derailing Cancer Care

Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
Current and Emerging Therapies for Relapsed and Refractory Multiple Myeloma

Experts review approved therapies and treatments still under investigation.
Changes in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should Persist

The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
ASCO and Friends: Cancer Patients Should Be Included in COVID-19 Vaccine Trials

A statement recommends including cancer patients and survivors in COVID-19 vaccine trials.

MULTIPLE MYELOMA NEWS

Oncopeptides Reconsiders Pepaxto Withdrawal Following Data Review

January 26, 2022

A nurse assists an older patient.

Daratumumab Prolongs PFS in Frail Patients With Multiple Myeloma

January 25, 2022

Patient with IV drip.

Melflufen Improves PFS, Not OS in Relapsed/Refractory Multiple Myeloma

January 24, 2022

IV drip

Daratumumab Dosing Frequency and Cost of Care in Multiple Myeloma

January 19, 2022

Gene research

5-Gene Risk Score Model Effectively Predicts Prognosis in Multiple Myeloma

January 12, 2022

Next post in Multiple Myeloma

A nurse assists an older patient.

Daratumumab Prolongs PFS in Frail Patients With Multiple Myeloma